

# UNCLASSIFIED

|                                                                                                                                                                                                                         |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                                                                                                                                                                                                                         |
|                                                                                                                                                                                                                         |
|                                                                                                                                                                                                                         |
|                                                                                                                                                                                                                         |
| AD NUMBER                                                                                                                                                                                                               |
| ADB281612                                                                                                                                                                                                               |
| NEW LIMITATION CHANGE                                                                                                                                                                                                   |
| TO<br>Approved for public release, distribution unlimited                                                                                                                                                               |
| FROM<br>Distribution authorized to U.S. Gov't. agencies only; Proprietary Info.; Sep 2001. Other requests shall be referred to US Army Medical Research and Materiel Comd., 504 Scott St., Fort Detrick, MD 21702-5012. |
| AUTHORITY                                                                                                                                                                                                               |
| USAMRMC ltr, 8 Jan 2003                                                                                                                                                                                                 |

THIS PAGE IS UNCLASSIFIED

AD \_\_\_\_\_

Award Number: DAMD17-98-1-8290

TITLE: Intracellular Signaling Pathways In Metastasis

PRINCIPAL INVESTIGATOR: Earl T. Sawai, Ph.D.

CONTRACTING ORGANIZATION: University of California, Davis  
Davis, California 95616

REPORT DATE: September 2001

TYPE OF REPORT: Final

PREPARED FOR: U.S. Army Medical Research and Materiel Command  
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Distribution authorized to U.S. Government agencies only (proprietary information, Sep 01). Other requests for this document shall be referred to U.S. Army Medical Research and Materiel Command, 504 Scott Street, Fort Detrick, Maryland 21702-5012.

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

20020814 201

## NOTICE

USING GOVERNMENT DRAWINGS, SPECIFICATIONS, OR OTHER DATA INCLUDED IN THIS DOCUMENT FOR ANY PURPOSE OTHER THAN GOVERNMENT PROCUREMENT DOES NOT IN ANY WAY OBLIGATE THE U.S. GOVERNMENT. THE FACT THAT THE GOVERNMENT FORMULATED OR SUPPLIED THE DRAWINGS, SPECIFICATIONS, OR OTHER DATA DOES NOT LICENSE THE HOLDER OR ANY OTHER PERSON OR CORPORATION; OR CONVEY ANY RIGHTS OR PERMISSION TO MANUFACTURE, USE, OR SELL ANY PATENTED INVENTION THAT MAY RELATE TO THEM.


### LIMITED RIGHTS LEGEND

Award Number: DAMD17-98-1-8290

Organization: University of California, Davis

Those portions of the technical data contained in this report marked as limited rights data shall not, without the written permission of the above contractor, be (a) released or disclosed outside the government, (b) used by the Government for manufacture or, in the case of computer software documentation, for preparing the same or similar computer software, or (c) used by a party other than the Government, except that the Government may release or disclose technical data to persons outside the Government, or permit the use of technical data by such persons, if (i) such release, disclosure, or use is necessary for emergency repair or overhaul or (ii) is a release or disclosure of technical data (other than detailed manufacturing or process data) to, or use of such data by, a foreign government that is in the interest of the Government and is required for evaluational or informational purposes, provided in either case that such release, disclosure or use is made subject to a prohibition that the person to whom the data is released or disclosed may not further use, release or disclose such data, and the contractor or subcontractor or subcontractor asserting the restriction is notified of such release, disclosure or use. This legend, together with the indications of the portions of this data which are subject to such limitations, shall be included on any reproduction hereof which includes any part of the portions subject to such limitations.

THIS TECHNICAL REPORT HAS BEEN REVIEWED AND IS APPROVED FOR PUBLICATION.

  
\_\_\_\_\_

7/15/02  
\_\_\_\_\_

\_\_\_\_\_

\_\_\_\_\_

# REPORT DOCUMENTATION PAGE

Form Approved  
OMB No. 074-0188

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302, and to the Office of Management and Budget, Paperwork Reduction Project (0704-0188), Washington, DC 20503

|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |                                                                     |                                                                    |                                                                         |  |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------|--------------------------------------------------------------------|-------------------------------------------------------------------------|--|
| <b>1. AGENCY USE ONLY (Leave blank)</b>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |                                                                     | <b>2. REPORT DATE</b><br>September 2001                            | <b>3. REPORT TYPE AND DATES COVERED</b><br>Final (1 Sep 98 - 31 Aug 01) |  |
| <b>4. TITLE AND SUBTITLE</b><br>Intracellular Signaling Pathways In Metastasis                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |                                                                     |                                                                    | <b>5. FUNDING NUMBERS</b><br>DAMD17-98-1-8290                           |  |
| <b>6. AUTHOR(S)</b><br>Earl T. Sawai, Ph.D.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |                                                                     |                                                                    |                                                                         |  |
| <b>7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES)</b><br>University of California, Davis<br>Davis, California 95616<br><br>E-mail: etsawai@ucdavis.edu                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |                                                                     |                                                                    | <b>8. PERFORMING ORGANIZATION<br/>REPORT NUMBER</b>                     |  |
| <b>9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES)</b><br>U.S. Army Medical Research and Materiel Command<br>Fort Detrick, Maryland 21702-5012                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |                                                                     |                                                                    | <b>10. SPONSORING / MONITORING<br/>AGENCY REPORT NUMBER</b>             |  |
| <b>11. SUPPLEMENTARY NOTES</b>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |                                                                     |                                                                    |                                                                         |  |
| <b>12a. DISTRIBUTION / AVAILABILITY STATEMENT</b><br>Distribution authorized to U.S. Government agencies only<br>(proprietary information, Sep 01). Other requests for this<br>document shall be referred to U.S. Army Medical Research and<br>Materiel Command, 504 Scott Street, Fort Detrick, Maryland 21702-5012.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |                                                                     |                                                                    | <b>12b. DISTRIBUTION CODE</b>                                           |  |
| <b>13. ABSTRACT (Maximum 200 Words)</b><br><br>We have preliminary evidence that both PI3K and PAK are differentially activated in the highly metastatic Met-1 tumors compared with the low metastatic Db-7 tumors. Furthermore, using micro array analysis, osteopontin (OPN), a protein linked to metastatic breast cancer in humans is differentially up regulated in Met-1 tumors compared with Db-7 tumors. We have confirmed the over expression of this gene product in Met-1 tumors by immunohistochemistry and immunoblot analysis. Further analyses are necessary to establish whether there is a linkage between PI3K/PAK activation and OPN expression. Preliminary data suggests that PyMT is capable of modulating the endocytosis of proteins expressed at the cell surface. Further study is required to confirm this observation. |                                                                     |                                                                    |                                                                         |  |
| <b>14. SUBJECT TERMS</b><br>Metastasis, signaling, polyoma middle t-antigen, transgenic mouse                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |                                                                     |                                                                    | <b>15. NUMBER OF PAGES</b><br>9                                         |  |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |                                                                     |                                                                    | <b>16. PRICE CODE</b>                                                   |  |
| <b>17. SECURITY CLASSIFICATION<br/>OF REPORT</b><br>Unclassified                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | <b>18. SECURITY CLASSIFICATION<br/>OF THIS PAGE</b><br>Unclassified | <b>19. SECURITY CLASSIFICATION<br/>OF ABSTRACT</b><br>Unclassified | <b>20. LIMITATION OF ABSTRACT</b><br>Unlimited                          |  |

NSN 7540-01-280-5500

Standard Form 298 (Rev. 2-89)  
Prescribed by ANSI Std. Z39-18  
298-102

## Table of Contents

|                                   |     |
|-----------------------------------|-----|
| Cover.....                        |     |
| SF 298.....                       | 2   |
| Table of Contents.....            | 3   |
| Introduction.....                 | 4   |
| Body.....                         | 4-6 |
| Key Research Accomplishments..... | 6-7 |
| Reportable Outcomes.....          | 7   |
| Conclusions.....                  | 7   |
| References.....                   | 7-8 |
| Appendices.....                   | 8   |

## 5. Introduction

Metastatic progression of tumors is a complex, multifactorial process that involves various steps such as cellular migration, implantation, neovascularization, and tissue colonization. The molecular sequence of events that are necessary for metastatic conversion is poorly understood. To better understand the mechanism(s) of breast cancer metastasis, we are studying the signaling pathways that control metastatic development. The focus of this project is to determine whether phosphatidylinositol 3-kinase (PI3K) or related signaling pathways are critical for metastatic progression. We hypothesize that PI3K links uncontrolled growth to the cell processes necessary for metastasis. We are utilizing a unique model system to study breast cancer metastasis. Specifically, we are examining two different genetically altered breast cancer tumor lines [called Met-1/Db-7 that are transformed with polyomavirus middle T-antigen (PyMT)] that vary in their metastatic potential when implanted into mice. Met-1 tumors are highly metastatic and are transformed by wild-type PyMT. In contrast, Db-7 tumors exhibit a low metastatic frequency and are transformed by a PyMT mutant that abrogates the ability of PyMT to bind and activate PI3K. Consequently, we are examining the signaling pathways that emanate from PyMT with a particular focus on the PI3K pathway, to determine whether these intracellular signaling pathways are critical for metastatic development. Furthermore, we are testing our hypothesis that PI3K activation is a critical determinant for metastatic development by transducing dominant-negative and constitutively active forms of PI3K and other signaling factors that are differentially activated or expressed in the Met-1 and Db-7 tumor lines. These transduced tumor lines will be assessed for their ability to metastasize after implantation of the tumors into the mammary fat pads of female nude mice. Thus, this project addresses the *in vitro* characterization of the PyMT transformed cells and the *in vivo* characterization of tumors transduced with genetic mutants of signaling proteins.

## 6. Body

### Statement of Work


The Specific Aims of the proposal are as follows:

- (1) Determine whether the difference in metastatic potential of the metastatic (Met-1) and non-metastatic (Db-7) mouse mammary tumor lines are due to alterations in PI3K activation and/or the signalling intermediates that emanate from the PI3K activation pathway.
- (2) Determine whether disruption of the PI3K activation pathway affects the metastatic and non-metastatic phenotypes *in vitro*. To achieve this goal, dominant-negative and constitutively-active mutants of PI3K and/or signalling intermediates in the PI3K pathway will be inducibly expressed using a novel tetracycline-inducible retroviral vector.
- (3) Analyze the metastatic potential of the tumor lines that inducibly express the transduced dominant-negative and constitutively-active regulatory mutants of PI3K and/or its signalling intermediates *in vivo*.

### Activation of PI3K signaling in Polyoma middle t-antigen transformed cells

Using PI3K assays, we have found that PI3K is activated by polyoma middle T-antigen transfected into murine Balb/c cells. This activation of PI3K was inhibited by treatment with 0.1mM wortmannin a PI3K inhibitor (Fig. 1).

Fig. 1. To prove that PI3K was activated in murine cells transformed by polyomavirus middle T-antigen, PI3K assay was performed on PI3K immunoprecipitates. PI3K immunoprecipitates were either untreated (lane 1, mock), or treated with DMSO (lane 2) or 0.1mM wortmannin (WM).



Further analyses were performed using the highly metastatic Met-1 and low metastatic Db-7 cells to determine whether PI3K was activated in these tumors. The results from these analyses demonstrated that PI3K was indeed activated in the Met-1 lines compared to the Db-7 lines. These results are consistent with previous studies that show that the double base mutation of polyomavirus middle T-antigen abrogates the interaction between PyMT and PI3K.

#### Polyoma middle T-antigen activates p21-Activated Kinase

It is likely that downstream signaling events important for metastatic progression. We tested whether PyMT was capable of activating PAK activation by performing in vitro kinase assays on PAK immunoprecipitates from murine cells transfected with PYMT (Fig. 2). We found that PAK was very strongly activated by PyMT. P21-activated kinases (PAK, a serine-threonine kinase) are activated through interactions with Ras-like G-proteins (Rac and Cdc42). These kinases also interact with guanine nucleotide exchange factors (Pix and Cool) and adapter proteins (Nck). PAK proteins have been shown to mediate growth factor-induced morphological changes involving actin-based cellular structures (i.e., formation of membrane ruffles and peripheral filopodia). These changes are critical for cellular mobility and locomotion. PAKs also modulate gene expression through activation of the Jun kinase (Jnk) signaling pathway. These results indicate that PAK activation is downstream of PyMT. We have preliminary evidence that PAK is differentially activated in the highly metastatic Met-1 tumors compared with the low metastatic Db-7 tumors.




Fig. 2

#### Osteopontin is differentially expressed in Met-1 tumors.

In collaboration with Dr. Jeff Gregg (Department of Medical Pathology, UC Davis), subtractive microarray analysis was performed on Met-1 and Db-7 tumors to determine whether specific genes were differentially expressed in metastatic versus non-metastatic tumors. Microarray analysis revealed that a gene that had previously been identified in metastatic breast cancer, osteopontin (OPN), was differentially expressed in the Met-1 tumors compared with the non-metastatic Db-7 tumors. This finding was supported by quantitative RT-PCR analysis that was performed on the Met-1 and Db-7 tumors (Fig 3).





Fig. 3. Quantitative RT-PCR analysis




Met-1 Db-7

Fig. 4.  
Immunohistochemical analysis of  
Met-1/Db-7 tumors using OPN  
monoclonal antibody

To confirm that OPN was differentially expressed in Met-1 tumors, immunohistochemistry (Fig. 4) and immunoblot analysis (Fig. 5) was performed on the Met-1 and Db-7 tumors. These results confirm that OPN is differentially expressed in the highly metastatic Met-1 tumors compared with the non-metastatic Db-7 tumors.

Fig. 5. Total cell extracts were prepared from three Met-1 and two Db-7 tumors from different mice (animal numbers are indicated). Proteins were separated on SDS-PAGE and transferred to nitrocellulose. Immunoblot analysis was performed with a monoclonal antibody to OPN and detected by ECL. The position of OPN is indicated on the right.




The results of these experiments reveal that Met-1 preferentially expresses osteopontin. These results are consistent with those from previous studies that indicate OPN is associated with metastatic breast cancer in humans. We are currently investigating whether the differential OPN expression is regulated by PI3K activation.

### Suppression of CD4 endocytosis by PyMT

HIV-1 and SIV Nef, a regulatory gene product necessary for AIDS pathogenesis, is known to bind and activate PAK and down regulate the expression of CD4 from the surface of Cos-7 cells cotransfected with CD4 and Nef. In our CD4-down regulation studies using Nef mutants, we included PyMT as a "negative" control. Unexpectedly, we found that the expression of PyMT enhanced the expression of CD4 on the cell surface by greater than 2-fold, as determined by FACS analysis. This is in contrast to Nef which down regulates the expression of CD4 from the cell surface by 30-40%. Because Nef has been shown to accelerate the endocytosis and degradation of CD4 expressed on the cell surface via the clathrin coated pit pathway, it is likely that PyMT is inhibiting the endocytosis of CD4.

Further analyses are in-progress to determine whether this inhibition is a specific or generalized effect involving other cell surface markers (such as cell adhesion molecules). We can conclude from our experiments that this effect is probably not due to PyMT effect on PI3K activation, however, additional studies using PyMT mutants that knock-out Src or PI3K association are in progress. These results may have important implications on the trafficking of cell surface molecules. If this property of PyMT affects tumor cell adhesion, this may reveal clues as to why cells transformed by PyMT (i.e., Met-1) may be highly metastatic.



## 7. Key Research Accomplishments

We have begun to characterize the intracellular signaling pathways that are influenced by the polyomavirus oncogene Middle T-antigen. Both PI3K and PAK are activated by PyMT in murine cells. We have preliminary evidence that both PI3K and PAK are differentially activated in the highly metastatic Met-1 tumors compared with the low metastatic Db-7 tumors. Furthermore, using micro array analysis, OPN, a protein linked to metastatic breast cancer in humans is differentially up regulated in Met-1 tumors compared with Db-7 tumors. We have confirmed the over expression of this gene product in Met-1 tumors by immunohistochemistry and immunoblot analysis. Further analyses are necessary to establish whether there is a linkage between PI3K/PAK activation and OPN

expression. Preliminary data suggests that PyMT is capable of modulating the endocytosis of proteins expressed at the cell surface. Further study is required to confirm this observation.

## 8. Reportable Outcomes

- Both phosphatidylinositol 3-kinase (PI3K) and p21 activated kinase (PAK) are activated by polyoma Middle T-antigen (PyMT) in murine cells.
- Osteopontin (OPN) is differentially expressed in the highly metastatic Met-1 tumors as compared with the low metastatic Db-7 tumors.
- Polyoma middle T-antigen appears to influence the endocytosis of specific molecules at the cell surface.

## 9. Conclusions

We have found that the cellular serine-threonine kinase p21-Activated Kinase is activated in Met-1 tumors and in murine cells transformed with the wild-type form of PyMT. We have evidence that PI3K is activated in the highly metastatic Met-1 cells compared with the low metastatic Db-7 cells. We are currently determining whether the activation of PAK by PyMT is dependent on PI3K activation. The activation of PAK by PyMT represents a previously unrecognized signaling pathway affected by PyMT that influences cell shape, morphology, and intracellular trafficking. We have also found that PyMT appears to inhibit the endocytosis of cellular proteins from the cell surface. The effect of PyMT on trafficking of surface receptors has not been described previously. The inhibition of receptor endocytosis may serve to prolong the ability of signaling molecules to maintain a proliferative or activation signal. Further studies regarding the role of PI3K activation on endocytosis and trafficking of surface proteins need to be performed to establish whether a linkage exists. Consistent with the idea that PI3K activation is necessary for metastatic conversion, is the observation that osteopontin (OPN) is differentially expressed in the highly metastatic Met-1 tumors compared with the low metastatic Db-7 tumors. These results provide a basic framework to examine the intracellular signaling pathways that are affected by metastatic development and progression. Results from this project may help in the development of new therapeutic approaches to prevent the progression of metastatic breast tumors as well as identify markers that would help in the detection and diagnosis of metastatic breast cancer.

## 10. References

- Guy, C.T., Cardiff, R.D., and Muller, W.J., 1992. Induction of mammary tumors by expression of polyomavirus middle T oncogene: a transgenic mouse model for metastatic disease. *Mol. Cell. Biol.*, **12**: 954-961.
- Cardiff, R.D. and Muller, W.J., 1993. Transgenic mouse models of mammary tumorigenesis. *Canc. Surveys*, **16**: 97-113.
- Cheung, A.T.W., Young, L.J.T., Chen, P.C.Y., Chao, C.Y., Ndoeye, A., Barry, P.A., Muller, W.J., and Cardiff, R.D., 1997. Microcirculation and metastasis in a new mouse mammary tumor model system. *Int. J. Oncology*, **11**: 69-77.
- Auger, K.R., Carpenter, C.L., Shoelson, S.E., Piwnicka-Worms, H., and Cantley, L.C., 1992. Polyoma virus middle T antigen-pp60c-src complex associates with purified phosphatidylinositol 3-kinase in vitro. *J. Biol. Chem.*, **267**: 5408-5415.
- Sawai, E.T., Baur, A., Struble, H., Peterlin, B.M., Levy, J.A., and Cheng-Mayer, C., 1994. Human immunodeficiency virus type 1 Nef associates with a cellular serine kinase in T lymphocytes. *Proc. Natl. Acad. Sci. USA*, **91**: 1539-1543.

Sawai, E.T., Khan, I.H., Montbriand, P.M., Peterlin, B.M., Cheng-Mayer, C., and Luciw, P.A., 1996. Activation of PAK by HIV and SIV Nef: Importance for AIDS in Rhesus Macaques. *Current Biol.*, **6**: 1519-1527.

Bourguignon, L.Y.W., Gunja-Smith, Z., Iida, N., Zhu, H.B., Young, L.J.T., and Cardiff, R.D. *CD44v3-containing isoform is responsible for vascular endothelial growth factors (VEGF) binding, membrane-cytoskeleton interaction, and matrix metalloproteinases (MMP-9) activation in metastatic breast tumor cells.* in *Am. Assoc. Cancer Res.* 1997. San Diego, CA:

Whitman, M., Kaplan, D.R., Scaffhausen, B., Cantley, L., and Roberts, T.M., 1985. Association of phosphatidylinositol kinase activity with polyoma middle-T competent for transformation. *Nature*, **315**: 239-242.

## **11. Appendices**

### **Abstracts**

Hamza, M.S., Cheung, A.T., Cardiff, R.D., and **Sawai, E.T.** Activation of Phosphatidylinositol 3'-kinase and p21-Activated kinase in Murine cells Transformed by Polyoma Middle T-antigen. Fourth Annual Cancer Research Symposium, UC Davis, September, 1999.



DEPARTMENT OF THE ARMY  
US ARMY MEDICAL RESEARCH AND MATERIEL COMMAND  
504 SCOTT STREET  
FORT DETRICK, MARYLAND 21762-5012

REPLY TO  
ATTENTION OF:

MCMR-RMI-S (70-1y)

8 Jan 2003

MEMORANDUM FOR Administrator, Defense Technical Information  
Center (DTIC-OCA), 8725 John J. Kingman Road, Fort Belvoir,  
VA 22060-6218

SUBJECT: Request Change in Distribution Statement

1. The U.S. Army Medical Research and Materiel Command has reexamined the need for the limitation assigned to the enclosed. Request the limited distribution statement for the enclosed be changed to "Approved for public release; distribution unlimited." These reports should be released to the National Technical Information Service.

2. Point of contact for this request is Ms. Judy Pawlus at DSN 343-7322 or by e-mail at judy.pawlus@det.amedd.army.mil.

FOR THE COMMANDER:

Encl

A handwritten signature in black ink, appearing to read "Phyllis M. Rinehart", is written over the typed name and title.

PHYLLIS M. RINEHART  
Deputy Chief of Staff for  
Information Management

ADB265840

ADB266633

ADB282069

ADB279138

ADB251763

ADB265386

ADB264578

ADB281601

ADB282057

ADB281679

ADB258874

ADB258251

ADB281645

ADB281773

ADB264541

ADB261128

ADB281660

ADB241630

ADB261339

ADB259064

ADB281924

ADB273096

ADB266141

ADB281663

ADB281681

ADB281664

ADB281659

ADB259637

ADB258830

ADB256645

ADB266029

ADB262441

ADB281668

ADB281674

ADB259834

ADB281771

ADB266075

ADB281612

ADB281661